Oct 31 (Reuters) - Surgical equipment maker Teleflex ( TFX )

reported a better-than-expected profit for the third

quarter on Thursday, helped by strong demand for its medical

devices.

Robust demand for non-urgent procedures, especially among

older adults, have kept investor expectations heightened around

the performance of medical device makers over the past year.

Peers such as Boston Scientific ( BSX ) and Stryker

have raised their full-year profit forecasts on resilient

demand.

Teleflex ( TFX ), which makes types of catheters and pumps, reported

a 2.4% rise in third-quarter revenue to $764.4 million, but

missed analysts' estimate of $769.6 million, according to data

compiled by LSEG.

CEO Liam Kelly said strong sales of the company's

bloodstream-related products as well as its heart and medical

imaging devices helped offset some "unexpected softness" in OEM

revenues.

Sales at the vascular access segment, through which Teleflex ( TFX )

makes medical devices for bloodstream-related procedures, rose

6.5% to $180.9 million.

The OEM segment, which designs and manufactures instruments

for other medical device makers, reported a marginal rise in

sales to $82.6 million.

On an adjusted basis, the company earned $3.49 per share in

the quarter ended Sept. 30, beating estimates of $3.39 per

share.

Teleflex ( TFX ) now expects its annual revenue to grow between 2.9%

and 3.4%, down from 3.4% to 4.4% growth previously expected.

The Wayne, Pennsylvania-based company also raised the lower

end of its 2024 adjusted per-share profit forecast to $13.90

from $13.80 previously, while keeping the upper end at $14.20.